Matthew Choy

Cooley advised Araris Biotech, a Swiss biotechnology company developing next-generation antibody-drug conjugates, on its definitive agreement to be acquired by Japan-based Taiho Pharmaceutical for up to $1.14 billion in cash.

Cooley advised the special committee of Checkpoint Therapeutics’ (Nasdaq: CKPT) board of directors in connection with Checkpoint’s definitive agreement to be acquired by Sun Pharmaceutical Industries (NSE: SUNPHARMA) for up to $416 million in cash and contingent value rights.

Cooley advised Personalis, a company transforming the active management of cancer through breakthrough personalized testing, on its expanded commercial relationship with Tempus AI, including an equity investment by Tempus into Personalis.

Cooley advised Reverence Capital Partners’ portfolio company Transact Campus, an innovative campus technology and payment solutions company, on a definitive agreement signed by Reverence Capital Partners to sell Transact to Roper Technologies for $1.6 billion.

Cooley advised Courier Health, a technology company reimagining how life sciences manufacturers engage and support patients, on its $16.5 million Series A financing. Norwest Venture Partners led the funding round with participation from existing investor, Work-Bench. Roy Moran, Norris Kadet and Matt Choy led the Cooley team advising Courier Health.